(Q35206348)

7 August 2017

1 reference

title

Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab (English)

1 reference

7 August 2017

1 reference

1 reference

Robert O Dillman

1

1 reference

7 August 2017

publication date

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

30

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

434-447

1 reference

Antibodies as cytotoxic therapy

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Magic bullets at last! Finally--approval of a monoclonal antibody for the treatment of cancer!!!

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Rituximab immunotherapy for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Rituximab: mechanism of action and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Rituximab in the treatment of refractory follicular lymphoma -- six doses are better than four.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Malignant tumors of the stomach. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900235-5

7 January 2021

10.1016/S0093-7754(03)00235-5

Identifiers

DOI

1 reference

7 August 2017

1 reference